CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
32.34
+0.10 (0.31%)
Nov 21, 2024, 4:00 PM EST - Market closed
CG Oncology Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for CG Oncology stock have an average target of 63.88, with a low estimate of 50 and a high estimate of 75. The average target predicts an increase of 97.53% from the current stock price of 32.34.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +131.91% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +131.91% | Nov 12, 2024 |
| UBS | UBS | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +85.53% | Oct 24, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +100.99% | Oct 8, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $66 | Buy | Initiates | $66 | +104.08% | Sep 23, 2024 |
Financial Forecast
Revenue This Year
1.04M
from 204.00K
Increased by 411.76%
Revenue Next Year
5.28M
from 1.04M
Increased by 405.27%
EPS This Year
-1.42
from -15.65
EPS Next Year
-1.82
from -1.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.8M | 34.1M | 140.3M | ||
| Avg | 1.0M | 5.3M | 110.3M | ||
| Low | n/a | n/a | 74.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,773.5% | 3,168.7% | 2,559.3% | ||
| Avg | 411.8% | 405.3% | 1,990.0% | ||
| Low | - | - | 1,319.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.25 | -1.47 | -0.20 |
| Avg | -1.42 | -1.82 | -1.32 |
| Low | -1.56 | -2.17 | -3.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.